Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

Raper, S. E., Chirmule, N. B., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,531

Adenoviruses: update on structure and function

Russell, W. C. (2008) · Journal of General Virology · doi:10.1099/vir.0.003087-0 · Cited by 462

Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

Barnes, E. J., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart, R., Smith, K., Townsend, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003155 · Cited by 404

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305

Virus-mediated gene delivery for human gene therapy

Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302

Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes

Parker, A. L., Waddington, S. N., Nicol, C. G., Shayakhmetov, D. M., Buckley, S. M. K., Denby, L., Kemball‐Cook, G., Ni, S., Lieber, A., McVey, J. H., et al. (2006) · Blood · doi:10.1182/blood-2006-04-008532 · Cited by 297

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

Mast, T. C., Kierstead, L. S., Gupta, S. B., Nikas, A. A., Kallas, E. G., Novitsky, V., Mbewe, B., Pitisuttithum, P., Schechter, M., Vardas, E., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.145 · Cited by 283

Adenovirus Receptors

Zhang, Y., & Bergelson, J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.19.12125-12131.2005 · Cited by 262

Trial watch

Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 260

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B gag/pol/nef Vaccine in Healthy Adults

Priddy, F. H., Brown, D. D., Kublin, J. G., Monahan, K., Wright, D. P., Lalezari, J. P., Santiago, S., Marmor, M. F., Lally, M., Novak, R. M., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587993 · Cited by 249

Integration Specificity of Phage ϕC31 Integrase in the Human Genome

Chalberg, T. W., Portlock, J. L., Olivares, E. C., Thyagarajan, B., Kirby, P. J., Hillman, R. T., Hoelters, J., & Calos, M. P. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.098 · Cited by 246

Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

Koski, A., Kangasniemi, L., Escutenaire, S., Pesonen, S. A., Cerullo, V., Diaconu, I., Nokisalmi, P., Raki, M., Rajecki, M., Guse, K., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.161 · Cited by 243

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses

Mok, H. S., Palmer, D. J., Ng, P., & Barry, M. A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.015 · Cited by 232

The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults

Abel, B., Tameris, M. D., Mansoor, N., Gelderbloem, S., Hughes, J., Abrahams, D. A., Makhethe, L., Erasmus, M., de Kock, M., van der Merwe, L., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200910-1484oc · Cited by 227

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

Hodgson, S. H. C., Duncan, C. J. A., Elias, S. C., Choudhary, P., Biswas, S., Halstead, F. D., Collins, K. A., Edwards, N. J., Douglas, A. D., Anagnostou, N. A., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.223 · Cited by 226

Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

Cerullo, V., Pesonen, S. A., Diaconu, I., Escutenaire, S., Arstila, P. T., Ugolini, M., Nokisalmi, P., Raki, M., Laasonen, L., Särkioja, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3567 · Cited by 226

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance

Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S., & Lillicrap, D. (2006) · Blood · doi:10.1182/blood-2006-06-032524 · Cited by 220

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

O’Hara, G. A., Duncan, C. J. A., Ewer, K., Collins, K. A., Elias, S. C., Halstead, F. D., Goodman, A. L., Edwards, N. J., Reyes‐Sandoval, A., Bird, P., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir850 · Cited by 214

Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting

Campos, S., & Barry, M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859062 · Cited by 210

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1

Carlisle, R. C., Di, Y., Cerny, A., Sonnen, A. F. ‐., Sim, R. B., Green, N. K., Šubr, V., Ulbrich, K., Gilbert, R. J. C., Fisher, K., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178459 · Cited by 203

Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1– and Neuropilin Receptor-1–Dependent Mechanisms

Lähteenvuo, J., Lähteenvuo, M., Kivelä, A., Hagberg, C. E., Falkevall, A., Klar, J., Heikura, T., Rissanen, T. T., Vähäkangas, E., Korpisalo, P., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.816454 · Cited by 199

Clearance of Adenovirus by Kupffer Cells Is Mediated by Scavenger Receptors, Natural Antibodies, and Complement

Xu, Z., Tian, J., Smith, J. S., & Byrnes, A. P. (2008) · Journal of Virology · doi:10.1128/jvi.01320-08 · Cited by 199

Current Issues and Future Directions of Oncolytic Adenoviruses

Yamamoto, M., & Curiel, D. T. (2009) · Molecular Therapy · doi:10.1038/mt.2009.266 · Cited by 197

Latest Insights on Adenovirus Structure and Assembly

Martı́n, C. S. (2012) · Viruses · doi:10.3390/v4050847 · Cited by 177

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

Gray, G., Buchbinder, S., & Duerr, A. C. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d2d2b · Cited by 172

Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients

Liikanen, I., Ahtiainen, L., Hirvinen, M., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S. A., Koski, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.51 · Cited by 170

Tumor detection and elimination by a targeted gallium corrole

Agadjanian, H., Ma, J., Rentsendorj, A., Valluripalli, V., Hwang, J. Y., Mahammed, A., Farkas, D. L., Gray, H. B., Gross, Z., & Medina‐Kauwe, L. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901531106 · Cited by 168

Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1

Benlahrech, A., Harris, J. D., Meiser, A., Papagatsias, T., Hornig, J., Hayes, P., Lieber, A., Athanasopoulos, T., Bachy, V. S., Csomor, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907898106 · Cited by 162

Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement

Xu, Z., Qiu, Q., Tian, J., Smith, J. S., Conenello, G. M., Morita, T., & Byrnes, A. P. (2013) · Nature Medicine · doi:10.1038/nm.3107 · Cited by 162

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

Gurwith, M., Lock, M. D., Taylor, E. M., Ishioka, G. Y., Alexander, J., Mayall, T., Ervin, J. E., Greenberg, R. N., Strout, C. B., Treanor, J. J., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70345-6 · Cited by 157

Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting

Khare, R., Chen, C. Y., Weaver, E. A., & Barry, M. A. (2011) · Current Gene Therapy · doi:10.2174/156652311796150363 · Cited by 156

Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural Infection

Bradley, R. R., Lynch, D. M., Iampietro, M. J., Borducchi, E. N., & Barouch, D. H. (2011) · Journal of Virology · doi:10.1128/jvi.06254-11 · Cited by 147

The influence of innate and pre‐existing immunity on adenovirus therapy

Zaiss, A. K., Machado, H. B., & Herschman, H. R. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22328 · Cited by 144

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

Frahm, N., deCamp, A. C., Friedrich, D. P., Carter, D. K., Defawe, O., Kublin, J. G., Casimiro, D. R., Duerr, A. C., Robertson, M. N., Buchbinder, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60202 · Cited by 141

Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients

Pesonen, S. A., Diaconu, I., Kangasniemi, L., Ranki, T., Kanerva, A., Pesonen, S. K., Gerdemann, U., Leen, A. M., Kairemo, K., Oksanen, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3001 · Cited by 140

The adenovirus capsid: major progress in minor proteins

Vellinga, J., van der Heijdt, S., & Hoeben, R. C. (2005) · Journal of General Virology · doi:10.1099/vir.0.80877-0 · Cited by 140

Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors

Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A., & Baker, A. H. (2010) · Viruses · doi:10.3390/v2102290 · Cited by 123

Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus

Doronin, K., Shashkova, E. V., May, S. M., Hofherr, S. E., & Barry, M. A. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.028 · Cited by 112

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

Kimball, K. J., Preuss, M. A., Barnes, M. N., Wang, M., Siegal, G. P., Wan, W., Kuo, H., Saddekni, S., Stockard, C. R., Grizzle, W. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0791 · Cited by 109

Cancer selective adenoviruses

Alemany, R. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.002 · Cited by 108

Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field

Majhen, D., Calderón, H., Chandra, N., Fajardo, C. A., Rajan, A., Alemany, R., & Custers, J. H. H. V. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.235 · Cited by 102

Development of hybrid viral vectors for gene therapy

Huang, S., & Kamihira, M. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.10.001 · Cited by 102

Use of adenovirus protein IX (pIX) to display large polypeptides on the virion—generation of fluorescent virus through the incorporation of pIX-GFP

Meulenbroek, R. A., Sargent, K. L., Lunde, J. A., Jasmin, B. J., & Parks, R. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.01.012 · Cited by 101

Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

Pesonen, S. A., Diaconu, I., Cerullo, V., Escutenaire, S., Raki, M., Kangasniemi, L., Nokisalmi, P., Dotti, G., Guse, K., Laasonen, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26216 · Cited by 99

Fully Detargeted Polyethylene Glycol-coated Adenovirus Vectors Are Potent Genetic Vaccines and Escape from Pre-existing Anti-adenovirus Antibodies

Wortmann, A., Vöhringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., Kochanek, S., & Kreppel, F. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300306 · Cited by 97

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

Hoft, D. F., Blazevic, A., Stanley, J., Landry, B., Sizemore, D. R., Kpamegan, E. P., Gearhart, J., Scott, A. J., Kik, S. V., Pau, M. G., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.048 · Cited by 94

Trial Watch:

Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Erbs, P., Limacher, J., Préville, X., Zitvogel, L., et al. (2014) · OncoImmunology · doi:10.4161/onci.28694 · Cited by 94

Aerosol and Lobar Administration of a Recombinant Adenovirus to Individuals with Cystic Fibrosis. II. Transfection Efficiency in Airway Epithelium

Perricone, M. A., Morris, J. E., Pavelka, K. L., Plog, M. S., O'Sullivan, B. P., Joseph, P. M., Dorkin, H. L., Lapey, A., Balfour, R., Meeker, D. P., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401750298544 · Cited by 91

Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer

Hemminki, O., Diaconu, I., Cerullo, V., Pesonen, S. K., Kanerva, A., Joensuu, T. K., Kairemo, K., Laasonen, L., Partanen, K. P. L., Kangasniemi, L., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.115 · Cited by 88

Oncolytic Viruses as Anticancer Vaccines

Woller, N., rlevik, E. G. ⁄., Ureche, C.-I., Schumacher, A., & hnel, F. K. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00188 · Cited by 87

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

Ogwang, C., Afolabi, M. O., Kimani, D., Jagne, Y. J., Hodgson, S. H. C., Bliss, C. M., Duncan, C. J. A., Collins, K. A., Garcia-Knight, M., Kimani, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057726 · Cited by 85

Requirements for Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X

Bradshaw, A. C., Parker, A. L., Duffy, M. R., Coughlan, L., van Rooijen, N., Kähäri, V., Nicklin, S. A., & Baker, A. H. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001142 · Cited by 84

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

Tamminga, C. L., Sedegah, M., Regis, D. P., Chuang, I., Epstein, J. E., Spring, M., Mendoza-Silveiras, J., McGrath, S. M., Maiolatesi, S. E., Reyes, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025868 · Cited by 80

Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1

Lambe, T., Carey, J. B., Li, Y., Spencer, A. J., van Laarhoven, A., Mullarkey, C. E., Vrdoljak, A., Moore, A., & Gilbert, S. C. (2013) · Scientific Reports · doi:10.1038/srep01443 · Cited by 76

Hyperactive Sleeping Beauty Transposase Enables Persistent Phenotypic Correction in Mice and a Canine Model for Hemophilia B

Mück-Häusl, M., Zhang, W., Müther, N., Rauschhuber, C., Franck, H. W. G., Merricks, E. P., Nichols, T. C., Kay, M. A., & Ehrhardt, A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.169 · Cited by 76

Adeno-associated Virus: A Key to the Human Genome?

Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71

From the first to the third generation adenoviral vector: What parameters are governing the production yield?

Dormond, E., Perrier, M., & Kamen, A. (2008) · Biotechnology Advances · doi:10.1016/j.biotechadv.2008.10.003 · Cited by 70

Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans

Peters, W., Brandl, J. R., Lindbloom, J. D., Martínez, C., Scallan, C. D., Trager, G. R., Tingley, D. W., Kabongo, M. L., & Tucker, S. N. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.01.023 · Cited by 69

Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines

Weaver, E. A., Nehete, P. N., Buchl, S. J., Senac, J. S., Palmer, D. J., Ng, P., Sastry, K. J., & Barry, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005059 · Cited by 68

Gene Therapy with Helper-Dependent Adenoviral Vectors: Current Advances and Future Perspectives

Vetrini, F., & Ng, P. (2010) · Viruses · doi:10.3390/v2091886 · Cited by 68

Redundant and Synergistic Mechanisms Control the Sequestration of Blood-born Adenovirus in the Liver

Paolo, N. C. D., van Rooijen, N., & Shayakhmetov, D. M. (2009) · Molecular Therapy · doi:10.1038/mt.2008.307 · Cited by 67

China offers alternative gateway for experimental drugs

Jia, H., & Kling, J. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-117 · Cited by 64

A Mechanistic Study of Tumor-Targeted Corrole Toxicity

Hwang, J. Y., Lubow, J., Chu, D., Ma, J., Agadjanian, H., Sims, J. D., Gray, H. B., Gross, Z., Farkas, D. L., & Medina‐Kauwe, L. K. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200094w · Cited by 63

Syrian Hamster as an Animal Model to Study Oncolytic Adenoviruses and to Evaluate the Efficacy of Antiviral Compounds

Wold, W. S. M., & Tóth, K. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00003-3 · Cited by 61

Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis

Appaiahgari, M. B., Saini, M., Rauthan, M., Jyoti, J., & Vrati, S. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.05.023 · Cited by 61

Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity

Hwang, J. Y., Lubow, D. J., Chu, D., Sims, J. D., Alonso-Valenteen, F., Gray, H. B., Gross, Z., Farkas, D. L., & Medina‐Kauwe, L. K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.015 · Cited by 60

Substitution of Adenovirus Serotype 3 Hexon onto a Serotype 5 Oncolytic Adenovirus Reduces Factor X Binding, Decreases Liver Tropism, and Improves Antitumor Efficacy

Short, J. J., Rivera, Á. A., Wu, H., Walter, M. R., Yamamoto, M., Mathis, J. M., & Curiel, D. T. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0332 · Cited by 59

Adenovirus Protein Involved in Virus Internalization Recruits Ubiquitin−Protein Ligases

Galinier, R., Gout, E., Lortat‐Jacob, H., Wood, J., & Chroboczek, J. (2002) · Biochemistry · doi:10.1021/bi020125b · Cited by 57

Systemic Delivery of a Novel Liver-Detargeted Oncolytic Adenovirus Causes Reduced Liver Toxicity but Maintains the Antitumor Response in a Breast Cancer Bone Metastasis Model

Zhang, Z., Krimmel‐Morrison, J. D., Zhang, Z., Hu, Z., & Seth, P. K. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.003 · Cited by 54

Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus

Liikanen, I., Monsurrò, V., Ahtiainen, L., Raki, M., Hakkarainen, T., Diaconu, I., Escutenaire, S., Hemminki, O., Dias, J. D., Cerullo, V., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.144 · Cited by 53

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

Peiperl, L., Morgan, C. A., Moodie, Z., Li, H., Russell, N. D., Graham, B. S., Tomaras, G. D., Rosa, S. C. D., McElrath, M. J., & the NIAID HIV Vaccine Trials Network (2010) · PLoS ONE · doi:10.1371/journal.pone.0013579 · Cited by 53

Comparative Cell‐Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV‐1 Clade BgagVaccine Prime‐Boost Regimens

Asmuth, D. M., Brown, E. L., DiNubile, M. J., Sun, X., del Rı́o, C., Harro, C. D., Keefer, M. C., Kublin, J. G., Dubey, S. A., Kierstead, L. S., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/648591 · Cited by 51

Viruses—from pathogens to vaccine carriers

Small, J. C., & Ertl, H. C. J. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.07.009 · Cited by 45

Increasing the Efficacy of Oncolytic Adenovirus Vectors

Tóth, K., & Wold, W. S. M. (2010) · Viruses · doi:10.3390/v2091844 · Cited by 43

Cardiovascular gene therapy with vascular endothelial growth factors

Ylä‐Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.051 · Cited by 40

An Infection-enhanced Oncolytic Adenovirus Secreting H. pylori Neutrophil-activating Protein with Therapeutic Effects on Neuroendocrine Tumors

Ramachandran, M., Yu, D., Wanders, A., Essand, M., & Eriksson, F. (2013) · Molecular Therapy · doi:10.1038/mt.2013.153 · Cited by 37

Adenovirus infection in cystic fibrosis patients: Implications for the use of adenoviral vectors for gene transfer

Rosenecker, J., Harms, K. H., Bertele, R. M., Pohl‐Koppe, A., von Mutius, E., Adam, D., & Nicolai, T. (1996) · Infection · doi:10.1007/bf01780642 · Cited by 33

Association of oncolytic adenoviruses with chemotherapies: An overview and future directions

Bressy, C., & Benihoud, K. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.003 · Cited by 33

Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression

Cao, H., Yang, T., Li, X.-F., Wu, J., Duan, C., Coates, A. L., & Hu, J. (2010) · Gene Therapy · doi:10.1038/gt.2010.125 · Cited by 32

Evaluation of an E1E4-Deleted Adenovirus Expressing the Herpes Simplex Thymidine Kinase Suicide Gene in Cancer Gene Therapy

Lanuti, M., Gao, G., Force, S. D., Chang, M. Y., Kouri, C. E., Amin, K. M., Hughes, J. V., Wilson, J. M., Kaiser, L. R., & Albelda, S. Μ. (1999) · Human Gene Therapy · doi:10.1089/10430349950018904 · Cited by 32

Seroprevalence of Neutralizing Antibodies to Adenovirus Type 5 among Children in India: Implications for Recombinant Adenovirus-Based Vaccines

Appaiahgari, M. B., Pandey, R. M., & Vrati, S. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00173-07 · Cited by 32

Investigating photoexcitation-induced mitochondrial damage by chemotherapeutic corroles using multimode optical imaging

Hwang, J. Y., Farkas, D. L., Lubow, D. J., Sims, J., Medina‐Kauwe, L. K., Gray, H. B., Mahammed, A., & Gross, Z. (2012) · Journal of Biomedical Optics · doi:10.1117/1.jbo.17.1.015003 · Cited by 28

The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma

Li, J., Liu, H., Li, L., Wu, H., Wang, C., YAN, Z., Wang, Y., Su, C., Jin, H., ZHOU, F., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.2217 · Cited by 28

LH3, a “homologue” of the mastadenoviral E1B 55-kDa protein is a structural protein of atadenoviruses

Gorman, J. J., Wallis, T. P., Whelan, D. A., Shaw, J. M., & Both, G. W. (2005) · Virology · doi:10.1016/j.virol.2005.07.020 · Cited by 24

Computationally designed adeno-associated virus (AAV) Rep 78 is efficiently maintained within an adenovirus vector

Sitaraman, V., Hearing, P., Ward, C. B., Gnatenko, D. V., Wimmer, E., Mueller, S., Skiena, S., & Bahou, W. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102883108 · Cited by 24

Novel Integrating Adenoviral/Retroviral Hybrid Vector for Gene Therapy

Murphy, S. J., Chong, H., Bell, S., Díaz, R. M., & Vile, R. G. (2002) · Human Gene Therapy · doi:10.1089/104303402317322302 · Cited by 23

Development of Adenovirus Capsid Proteins for Targeted Therapeutic Delivery

Medina‐Kauwe, L. K. (2013) · Therapeutic Delivery · doi:10.4155/tde.12.155 · Cited by 22

HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice

MacLeod, S. H., Elgadi, M., Bossi, G., Sankar, U., Pisio, A. C., Agopsowicz, K. C., Sharon, D. M., Graham, F. L., & Hitt, M. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.79 · Cited by 19

Gene therapy for cystic fibrosis: which postman, which box?

Middleton, P. G., & Alton, E. W. F. W. (1998) · Thorax · doi:10.1136/thx.53.3.197 · Cited by 18

Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds

Behr, M., Kaufmann, J. K., Ketzer, P., Engelhardt, S., Mück-Häusl, M., Okun, P. M., Petersen, G., Neipel, F., Hassel, J. C., Ehrhardt, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095723 · Cited by 17

Oncolytic Immunotherapy: Where Are We Clinically?

Hemminki, A. (2014) · Scientifica · doi:10.1155/2014/862925 · Cited by 17

Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma

Kuhlmann, K. F. D., van Geer, M. A., Bakker, C., Dekker, J., Havenga, M. J. E., Elferink, R. P. J. O., Gouma, D. J., Bosma, P. J., & Wesseling, J. G. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.4 · Cited by 13

A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein

Matsui, H., Sakurai, F., Katayama, K., Abe, Y., Machitani, M., Kurachi, S., Tachibana, M., & Mizuguchi, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.046 · Cited by 11

Vector and Helper Genome Rearrangements Occur During Production of Helper-Dependent Adenoviral Vectors

Ahn, M., Gamble, A., Witting, S. R., Magrisso, I. J., Surendran, S., Obici, S., & Morral, N. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.198 · Cited by 8

A Novel Hybrid Adenoretroviral Vector with More Extensive E3 Deletion Extends Transgene Expression in Submandibular Glands

Zheng, C., Cotrim, A. P., Nikolov, N. P., Mineshiba, F., Swaim, W. D., & Baum, B. J. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.175 · Cited by 7

Efficient liver-directed gene transfer by in situ generation of retroviral vector from adenoviral templates.

Harris, J. D., Roberts, M. L., Perumal, D., Graham, I. R., Patterson, S., & Dickson, G. (2009) · PubMed · Cited by 2

Gene Therapy Leaves a Vicious Cycle

Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D. M., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 366

Viral vector‐based gene therapies in the clinic

Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269

Oral vaccination of fish: Lessons from humans and veterinary species

Embregts, C. W. E., & Forlenza, M. (2016) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2016.03.024 · Cited by 178

Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair

Cucchiarini, M., & Madry, H. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0125-2 · Cited by 133

Gene therapy and genome surgery in the retina

DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127

Adenoviral vectors: development and application

Zhang, W.-W. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.10.1419 · Cited by 10

Adenovirus Vectors: Excellent Tools for Vaccine Development

Chang, J. (2021) · Immune Network · doi:10.4110/in.2021.21.e6 · Cited by 129

Recombinat adenovirus vectors for gene therapy and clinical trials (A review)

Nasz, I., & Ádám, É. (2001) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.48.2001.3-4.6 · Cited by 17

Recombinant Adenoviruses as Vaccines

Randrianarison-Huetz, V., & Perricaudet, M. (1995) · Biologicals · doi:10.1006/biol.1995.0025 · Cited by 75

Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses

Park, A., & Lee, J. Y. (2024) · The Journal of Microbiology · doi:10.1007/s12275-024-00159-4 · Cited by 28